GXF-111, a proteolysis targeting chimera (PROTAC) molecule, efficiently induces the selective degradation of the BRD3 and BRD4-L proteins. It exhibits high binding affinities to both BRD3 BD1 and BRD3 BD2, with K i values of 11.97 nM and 2.35 nM, respectively. This compound is utilized in cancer research [1].

GXF-111 (Compound 24) exhibits binding affinity for BRD3 BD1 and BRD3 BD2 domains, with K_i values of 11.97 nM and 2.35 nM, respectively [1]. It demonstrates cytotoxic activity in MV4-11 and MM.1S cell lines, with IC_50 values of 6.31 nM and 95.2 nM, respectively [1]. GXF-111 (2, 10 nM; 24 h) effectively inhibits cell growth in MM.1S cells by degrading BET family proteins [1]. Furthermore, GXF-111 (4 days) shows antiproliferative activity across seven human cancer cell lines, with IC_50 values ranging from 6.31 nM to 17.25 μM [1].